[go: up one dir, main page]

PL1618128T3 - Szczepionka przeciwko gruźlicy o ulepszonej skuteczności - Google Patents

Szczepionka przeciwko gruźlicy o ulepszonej skuteczności

Info

Publication number
PL1618128T3
PL1618128T3 PL04729090T PL04729090T PL1618128T3 PL 1618128 T3 PL1618128 T3 PL 1618128T3 PL 04729090 T PL04729090 T PL 04729090T PL 04729090 T PL04729090 T PL 04729090T PL 1618128 T3 PL1618128 T3 PL 1618128T3
Authority
PL
Poland
Prior art keywords
nucleic acid
acid molecules
improved efficacy
tuberculosis vaccine
present
Prior art date
Application number
PL04729090T
Other languages
English (en)
Inventor
Leander Grode
Stefan H E Kaufmann
Bärbel Raupach
Jürgen Hess
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Publication of PL1618128T3 publication Critical patent/PL1618128T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
PL04729090T 2003-04-23 2004-04-23 Szczepionka przeciwko gruźlicy o ulepszonej skuteczności PL1618128T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46464403P 2003-04-23 2003-04-23
EP04729090A EP1618128B1 (en) 2003-04-23 2004-04-23 Tuberculosis vaccine with improved efficacy
PCT/EP2004/004345 WO2004094469A1 (en) 2003-04-23 2004-04-23 Tuberculosis vaccine with improved efficacy

Publications (1)

Publication Number Publication Date
PL1618128T3 true PL1618128T3 (pl) 2010-12-31

Family

ID=33310924

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04729090T PL1618128T3 (pl) 2003-04-23 2004-04-23 Szczepionka przeciwko gruźlicy o ulepszonej skuteczności

Country Status (23)

Country Link
US (2) US7988980B2 (pl)
EP (1) EP1618128B1 (pl)
JP (1) JP4662925B2 (pl)
KR (1) KR101101263B1 (pl)
CN (1) CN1798762B (pl)
AT (1) ATE473238T1 (pl)
AU (1) AU2004232485B2 (pl)
BR (1) BRPI0409789B8 (pl)
CA (1) CA2523084C (pl)
CU (1) CU23608A3 (pl)
CY (1) CY1110793T1 (pl)
DE (1) DE602004028000D1 (pl)
DK (1) DK1618128T3 (pl)
ES (1) ES2344698T3 (pl)
HR (1) HRP20100395T1 (pl)
MX (1) MXPA05011360A (pl)
PL (1) PL1618128T3 (pl)
PT (1) PT1618128E (pl)
RU (1) RU2342400C2 (pl)
SI (1) SI1618128T1 (pl)
UA (1) UA91180C2 (pl)
WO (1) WO2004094469A1 (pl)
ZA (1) ZA200508276B (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7988980B2 (en) * 2003-04-23 2011-08-02 Max-Planck-Gesellschaft Zur Foerderung Der Wissenshaften E. V. Tuberculosis vaccine with improved efficacy
EP1649869A1 (en) * 2004-10-21 2006-04-26 Vakzine Projekt Management GmbH Combination of a recombinant mycobacterium and a biologically active agent as a vaccine
ES2366622T3 (es) 2004-12-01 2011-10-24 Aeras Global Tb Vaccine Foundation Cepas de bcg recombinante con capacidad potenciada para escapar del endosoma.
EP2818178A1 (en) * 2008-01-11 2014-12-31 The Government of The United States of America as represented by The Secretary, Department of Health and Human Services Polypeptide vaccine and vaccination strategy against mycobacterium
WO2011031139A1 (en) 2009-09-09 2011-03-17 Universiteit Utrecht Holding B.V. An ataq protein or a part thereof as a vaccine
SA110310855B1 (ar) 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي
BR112013004389A2 (pt) 2010-08-27 2016-05-17 Pantarhei Bioscience Bv método imunoterapêutico para tratamento do câncer de próstata
SI3360569T1 (sl) * 2010-09-20 2020-07-31 Vakzine Projekt Management Gmbh Rekombinantna mycobacterium kot cepivo za uporabo pri ljudeh
EP2638062B1 (en) 2010-11-10 2018-04-25 Laboratorios LETI, S.L. New adjuvant
BR112013015882B8 (pt) * 2010-12-21 2021-01-05 Max Planck Gesellschaft célula recombinante de mycobacterium bovis (m. bovis) do bacillus calmette-guérin (bcg) da cepa danish subtipo prague e uso da mesma
ES2569035T3 (es) 2010-12-21 2016-05-06 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Determinación de la eficacia de una vacunación anti-micobacteriana recombinante viva
RU2520078C1 (ru) * 2013-04-25 2014-06-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации (ФГБУ "НИИЭМ им. Н.Ф. Гамалеи" Минздрава России) СПОСОБ ПОЛУЧЕНИЯ ИММУНОГЕННОЙ КОМПОЗИЦИИ НА ОСНОВЕ ГИБРИДНОГО БЕЛКА Ag85A-DBD И ДЕКСТРАНА, РЕКОМБИНАНТНАЯ ПЛАЗМИДА pAg85A-DBD, ШТАММ Escherichia coli [pREP4, pAg85A-DBD], ХИМЕРНЫЙ БЕЛОК Ag85A-DBD
WO2016080830A2 (en) 2014-11-18 2016-05-26 Pantarhei Bioscience B.V. Immunotherapeutic method for treating pancreatic cancer
EP3090757A1 (en) * 2015-05-04 2016-11-09 Vakzine Projekt Management GmbH Recombinant mycobacterium as an immunotherapeutic agent for the treatment of cancer
EP3349790A1 (en) 2015-09-18 2018-07-25 Rijksuniversiteit Groningen Long chain inulin for stimulating an immune response
KR101825439B1 (ko) * 2016-04-15 2018-02-05 배재대학교 산학협력단 염산 처리에 의한 그람양성 박테리아 고스트의 제조 방법
WO2018184188A1 (en) * 2017-04-07 2018-10-11 Chengdu Yongan Pharmaceutical Co., Ltd. RECOMBINANT BCG OVEREXPRESSING phoP-phoR
JP7169340B2 (ja) * 2017-07-25 2022-11-10 オーロラ ラブズ リミテッド 車両ｅｃｕソフトウェアのためのソフトウェアデルタ更新の構築およびツールチェーンに基づく異常検出
RU2678175C1 (ru) * 2018-03-16 2019-01-23 федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа имени А.А. Смородинцева" Министерства здравоохранения Российской Федерации (ФГБУ "НИИ гриппа им. А.А. Смородинцева" Минздрава России) Рекомбинантный штамм вируса гриппа A/PR8/HK-NS80E85A, экспрессирующий фрагменты антигенов ESAT-6 и Ag85A M.tuberculosis, для получения векторной вакцины против туберкулеза
CN111979162B (zh) * 2019-05-22 2024-02-13 上海市公共卫生临床中心 重组卡介苗菌株、其制备方法和用途
WO2021228363A1 (en) 2020-05-11 2021-11-18 Vakzine Projekt Management Gmbh Prevention of infectious diseases by modulating the immune system
WO2021228768A1 (en) 2020-05-11 2021-11-18 Vakzine Projekt Management Gmbh Prevention of infectious diseases by modulating the immune system
KR20230084177A (ko) * 2020-10-09 2023-06-12 제리아 신야쿠 고교 가부시키 가이샤 결핵균 추출물의 신규 용도
EP4122491A1 (en) 2021-07-22 2023-01-25 Vakzine Projekt Management GmbH Recombinant microbacterium as an immunotherapeutic agent for the second-line therapy of bladder carcinoma
EP4373519A1 (en) 2021-07-22 2024-05-29 Serum Life Science Europe GmbH Recombinant mycobacterium as an immunotherapeutic agent for the second-line therapy of bladder carcinoma

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9713959A (pt) * 1996-12-18 2000-04-11 Stanford Rook Ltd Uso de material antigênico e/ou imunorregulatório derivado da mycobacterium vaccae, composição compreedendo o mesmo, e, processo para regulação descendente da atividade th2 do sistema imunológico de um indivìduo
EP0902086A1 (en) 1997-08-22 1999-03-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tuberculosis vaccine
US7988980B2 (en) * 2003-04-23 2011-08-02 Max-Planck-Gesellschaft Zur Foerderung Der Wissenshaften E. V. Tuberculosis vaccine with improved efficacy

Also Published As

Publication number Publication date
CU23608A3 (es) 2010-12-08
CA2523084C (en) 2012-09-04
PT1618128E (pt) 2010-10-13
US20120027794A1 (en) 2012-02-02
BRPI0409789B8 (pt) 2021-05-25
US20070134267A1 (en) 2007-06-14
JP2007524367A (ja) 2007-08-30
ES2344698T3 (es) 2010-09-03
EP1618128B1 (en) 2010-07-07
US7988980B2 (en) 2011-08-02
BRPI0409789A (pt) 2006-05-30
BRPI0409789B1 (pt) 2018-10-16
UA91180C2 (ru) 2010-07-12
ATE473238T1 (de) 2010-07-15
DK1618128T3 (da) 2010-10-18
AU2004232485B2 (en) 2009-11-26
HK1091217A1 (zh) 2007-01-12
CY1110793T1 (el) 2015-06-10
AU2004232485A1 (en) 2004-11-04
KR20050114281A (ko) 2005-12-05
KR101101263B1 (ko) 2012-01-04
CN1798762A (zh) 2006-07-05
ZA200508276B (en) 2006-06-28
SI1618128T1 (sl) 2010-11-30
RU2005136354A (ru) 2006-03-20
MXPA05011360A (es) 2005-11-28
RU2342400C2 (ru) 2008-12-27
US8545854B2 (en) 2013-10-01
HRP20100395T1 (hr) 2010-09-30
DE602004028000D1 (de) 2010-08-19
CN1798762B (zh) 2010-04-28
WO2004094469A1 (en) 2004-11-04
CA2523084A1 (en) 2004-11-04
EP1618128A1 (en) 2006-01-25
JP4662925B2 (ja) 2011-03-30

Similar Documents

Publication Publication Date Title
PL1618128T3 (pl) Szczepionka przeciwko gruźlicy o ulepszonej skuteczności
DE69836588D1 (de) Tuberkulose impfstoff
WO2008140812A3 (en) Compositions and methods comprising klk3, psca, or folh1 antigen
NO20072470L (no) Malariaigangsetter/forsterkervaksine
MX351247B (es) Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
NZ596658A (en) Dig-10 insecticidal cry toxins
SG164344A1 (en) Immunogens from uropathogenic escherichia coli
WO2007067681A3 (en) Immunostimulatory compositions and methods
WO2007062656A3 (en) A nucleotide vaccine
TW200740841A (en) Polypeptides having antimicrobial activity and polynucleotides encoding same
EP1572918A4 (en) SYNTHETIC GLYCOLIPOPEPTIDES AS VACCINES
WO2007024947A3 (en) Canine influenza vaccines
ATE321853T1 (de) Humanische pellino-polypeptide
TW200621284A (en) Polypeptides having antimicrobial activity and polynucleotides encoding same
TW200510460A (en) Antimicrobial polypeptides
TW200734350A (en) Polypeptides having antimicrobial activity and polynucleotides encoding same
SG146640A1 (en) Isolated photoprotein mtclytin, and use thereof
DK1962889T3 (da) Immunogent polypeptid nestående af tumorantigenafledte optimerede kryptiske peptider samt anvendelser deraf
DE60239753D1 (de) Impfstoff gegen infektiöses lachsanämievirus
TW200502253A (en) Antimicrobial polypeptides
GB2403477B (en) Recombinant BCG strains expressing alanine dehydrogenase,serine dehydratase and/or glutamine synthetase as TB vaccines
GB0409559D0 (en) Polypeptide
TW200700076A (en) Polypeptides having antimicrobial activity and polynucleotides encoding same
TW200621285A (en) Polypeptides having antimicrobial activity and polyncleotides encoding same
EP1828237A4 (en) HUMAN CANCER SUPPRESSOR GENE, PROTEIN ENCODED THEREIN, EXPRESSION VECTOR CONTAINING THE GENE, AND CELL TRANSFORMED BY THE VECTOR